In 2017, Domain Therapeutics and Pfizer signed a collaboration agreement to accelerate the validation of novel GPCR drug targets using bioSens-All™ (see press release)
Multi-target collaboration for rare diseases
- Phase I
The multi-target drug discovery program aims at validating potential targets across a range of therapeutic indications by probing the structure-function relationships of various amino acid substitutions in each GPCRs.
The collaboration is based on our proprietary platform bioSens-All™ which enables to assess the impact of mutations on different signaling pathways engaged by GPCRs.